34
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Molecular understanding of hyperglycemia's adverse effects for diabetic complications.

      1 ,
      JAMA
      American Medical Association (AMA)

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Diabetic complications are the major cause of morbidity and mortality in persons with diabetes. Chronic hyperglycemia is a major initiator of diabetic microvascular complications (eg, retinopathy, neuropathy, nephropathy). Glucose processing uses a variety of diverse metabolic pathways; hence, chronic hyperglycemia can induce multiple cellular changes leading to complications. Several predominant well-researched theories have been proposed to explain how hyperglycemia can produce the neural and vascular derangements that are hallmarks of diabetes. These theories can be separated into those that emphasize the toxic effects of hyperglycemia and its pathophysiological derivatives (such as oxidants, hyperosmolarity, or glycation products) on tissues directly and those that ascribe pathophysiological importance to a sustained alteration in cell signaling pathways (such as changes in phospholipids or kinases) induced by the products of glucose metabolism. This article summarizes these theories and the potential therapeutic interventions that may prevent diabetic complications in the presence of hyperglycemia, control of which is often difficult with current therapeutic options.

          Related collections

          Author and article information

          Journal
          JAMA
          JAMA
          American Medical Association (AMA)
          0098-7484
          0098-7484
          Nov 27 2002
          : 288
          : 20
          Affiliations
          [1 ] Lilly Research Laboratories, Indianapolis, Ind, USA.
          Article
          jsc20037
          10.1001/jama.288.20.2579
          12444865
          c95de61b-d7a7-43fd-bbb9-f5189191aa8d
          History

          Comments

          Comment on this article